EBS Financial Facts
Weighted-average number of shares - diluted: 49.44MResearch and development: 27.19M
See Full Income Statement
Inventories: 81.16M
Income tax receivable, net: 11.83M
See Full Balance Sheet
Emergent BioSolutions, Inc. (EBS) Earnings
|
Expand Research on EBS
| Next EPS Date | 8/11/26 | EPS Growth Rate | -31.3% |
|---|---|---|---|
| Average EPS % Beat Rate | +4.0% | Revenue Growth Rate | +32.0% |
| Average % Move 1-Wk after EPS | -6.0% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
8/11/26  |
Q226 | N/A | $0.11 | N/A | N/A | $186M | N/A | N/A | N/A | ||
| 4/30/26 |
Q126 | $0.21 | $0.86 | -$0.65 | $156.1M | $205M | N/A |  | | Details | |
| 2/26/26 | Q425 | -$0.43 | $0.38 | -$0.81 | $148.7M | $237M | N/A | | | Details | |
| 10/29/25 |
Q325 | N/A | $0.05 | N/A | $231.1M | $203.67M | N/A | N/A | N/A | ||
| 8/6/25 |
Q225 | $0.16 | -$0.10 | +$0.26 | $140.9M | $174M | N/A | | | Details | |
| 5/7/25 |
Q125 | $0.71 | $0.49 | +$0.22 | $222.2M | $279M | N/A | | | Details | |
| 4/24/25 |
Q125 | N/A | $0.49 | N/A | N/A | $279M | N/A | N/A | N/A | ||
| 2/20/25 |
Q424 | N/A | -$0.41 | N/A | N/A | $243.33M | = | N/A | N/A |
